CRIS Negative Sentiment
UNAUDITED FINANCIAL INFORMATION CURIS, INC. AND SUBSIDIARIES Unaudited Condensed Consolidated Balance Sheets (In thousands, except share and per share data) BiopharmaWatch Research Key Takeaway: Curis, Inc. has released its unaudited financial information for the fiscal year ending December 31, 2024. The company reported a total revenue of $10,908, an increase from $10,023 in the previous year. However, total assets have sharply decreased to $41,265 while total stockholders' equity now reflects a deficit of $5,998. The net loss for the year stands at $43,389, showing an improvement from the prior year's loss of $47,413.
Price reaction · baseline $48.2 (2025-03-27 close) · hit after-hours · clean, no other CRIS news in the window
Market Sentiment Analysis
BiopharmaWatch Analysis From our catalyst data and publicly available data · not financial advice Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia
Full Press Release Details UNAUDITED FINANCIAL INFORMATION
CURIS, INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
December 31, 2024 2023 ASSETS Cash, cash equivalents and investments $ 19,997 $ 56,334 Restricted cash 544 544 Accounts receivable 3,349 2,794 Prepaid expenses and other assets 4,999 5,138 Property and equipment, net 231 434 Operating lease right-of-use asset 3,163 3,056 Goodwill 8,982 8,982 Total assets $ 41,265 $ 77,282 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Accounts payable and accrued liabilities $ 10,135 $ 12,212 Operating lease liability 2,954 2,794 Liability related to sale of future royalties, net 34,174 42,606 Total liabilities 47,263 57,612 Total stockholders' equity (deficit) (5,998) 19,670 Total liabilities and stockholders' equity (deficit) $ 41,265 $ 77,282
CURIS, INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
Years Ended December 31, 2024 2023 Revenues, net $ 10,908 $ 10,023 Operating expenses Cost of royalties 98 212 Research and development 38,562 39,496 General and administrative 16,790 18,647 Total operating expenses 55,450 58,355 Loss from operations (44,542) (48,332) Total other income 1,153 919 Net loss $ (43,389) $ (47,413) Net loss per common share (basic and diluted) $ (6.88) $ (8.96) Weighted average common shares (basic and diluted) 6,306,284 5,293,294
Frequently Asked Questions What were Curis, Inc.'s total assets as of December 31, 2024? Curis, Inc.'s total assets were $41,265,000 as of December 31, 2024.
How much was the net loss reported by Curis for 2024? The net loss reported by Curis for 2024 was $43,389,000.
What were the total operating expenses for Curis in 2024? Total operating expenses for Curis in 2024 amounted to $55,450,000.
What was Curis's net loss per share in 2024? Curis's net loss per common share in 2024 was $6.88.
How did Curis's cash and investments change from 2023 to 2024? Curis's cash and investments decreased from $56,334,000 in 2023 to $19,997,000 in 2024.
Tags: CRIS Viatris Investor Conferences Healthcare Curis financial report net loss stockholders' equity 2024